MEDICINES CONTROL COUNCIL
|
|
|
- Warren Bradley
- 6 years ago
- Views:
Transcription
1 Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 33/2.9/0498 PHARMACHEMIE (PTY) 33/2.9/0499 PHARMACHEMIE (PTY) 33/2.9/0500 PHARMACHEMIE (PTY) 33/2.9/0501 PHARMACHEMIE (PTY) 38/34/0031 STRIDES SA A39/23/0180 FRESENIUS KABI SOUTH AFRICA PCH CR 10 PCH CR 30 PCH CR 60 PCH CR 100 DAS FLUMAZENIL 0,1 mg/ml AMINOVEN 5 % 30,0 mg 60,0 mg 100,0 mg Each 1,0 ml solution contains: FLUMAZENIL 0,1 mg Each 1 000,0 ml solution contains: L-ISOLEUCINE 2,5 g L-LEUCINE 3,7 g L-METHIONINE 2,15 g L-LYSINE ACETATE equivalent to L-LYSINE 4,655 g L-PHENYLALANINE 2,55 g L-THREONINE 2,2 g L-TRYPTOPHAN 1,0 g L-VALINE 3,1 g L-ARGININE 6,0 g L-HISTIDINE 1,5 g L-ALANINE 7,0 g GLYCINE 5,5 g L-PROLINE 5,6 g L-SERINE 3,25 g L-TYROSINE 0,2 g TAURINE 0,5 g 12.68_Notification_of Sep12_v1 Oct 2012 Page 1 of 10
2 A39/23/0181 A39/23/0183 A40/20.2.2/0437 A40/20.2.2/0438 FRESENIUS KABI SOUTH AFRICA FRESENIUS KABI SOUTH AFRICA ZYDUS HEALTHCARE SA ZYDUS HEALTHCARE SA AMINOVEN 10 % AMINOVEN 15 % ZYDUS FLUCONAZOLE 150 mg ZYDUS FLUCONAZOLE 200 mg Notification of of Medicines Each 1 000,0 ml solution contains: L-ISOLEUCINE 5,0 g L-LEUCINE 7,4 g L-METHIONINE 4,3 g L-LYSINE ACETATE equivalent to L-LYSINE 9,31 g L-PHENYLALANINE 5,1 g L-THREONINE 4,4 g L-TRYPTOPHAN 2,0 g L-VALINE 6,2 g L-ARGININE 12,0 g L-HISTIDINE 3,0 g L-ALANINE 14,0 g GLYCINE 11,0 g L-PROLINE 11,2 g L-SERINE 6,5 g L-TYROSINE 0,4 g TAURINE 1,0 g Each 1 000,0 ml solution contains: L-ISOLEUCINE 5,2 g L-LEUCINE 8,9 g L-METHIONINE 3,8 g L-LYSINE ACETATE equivalent to L-LYSINE 15,655 g L-PHENYLALANINE 5,5 g L-THREONINE 8,6 g L-TRYPTOPHAN 1,6 g L-VALINE 5,5 g L-ARGININE 20,0 g L-HISTIDINE 7,3 g L-ALANINE 25,0 g GLYCINE 18,5 g L-PROLINE 17,0 g L-SERINE 9,6 g L-TYROSINE 0,4 g TAURINE 2,0 g FLUCONAZOLE 150,0 mg FLUCONAZOLE 200,0 mg 41/21.2/0354 MSD JANUVIA 25 SITAGLIPTIN PHOSPATE SITAGLIPTIN 25,0 mg 41/21.2/0355 MSD JANUVIA 50 SITAGLIPTIN PHOSPATE SITAGLIPTIN 50,0 mg 12.68_Notification_of Sep12_v1 Oct 2012 Page 2 of 10
3 Notification of of Medicines 41/21.2/0356 MSD JANUVIA 100 SITAGLIPTIN PHOSPATE SITAGLIPTIN 100,0 mg 42/11.10/0263 RECKITT BENCKISER 42/26/0327 ACCORD HEALTHCARE 42/26/0328 ACCORD HEALTHCARE 42/26/0329 ACCORD HEALTHCARE GAVISCON PLUS TABLETS ACCORD MIDAZOLAM 15 mg/3 ml ACCORD MIDAZOLAM 50 mg/10 ml ACCORD MIDAZOLAM 5 mg/5 ml SODIUM ALGINATE 250,0 mg SODIUM BICARBONATE 106,5 mg CALCIUM CARBONATE 187,5 mg Each 3,0 ml solution contains: MIDAZOLAM 15,0 mg Each 10,0 ml solution contains: MIDAZOLAM 50,0 mg Each 5,0 ml solution contains: MIDAZOLAM 5,0 mg 42/11.5/0408 NORGINE MACROLYTE Each sachet of powder contains: POLYETHYLENE GLYCOL ,125 g SODIUM BICARBONATE 178,5 mg SODIUM CHLORIDE 350,07 mg POTASSIUM CHLORIDE 46,6 mg 42/11.5/0409 NORGINE ISOPEG Each sachet of powder contains: POLYETHYLENE GLYCOL ,125 g SODIUM BICARBONATE 178,5 mg SODIUM CHLORIDE 350,07 mg POTASSIUM CHLORIDE 46,6 mg 42/20.2/0567 BIOTECH LABORATORIES (PTY) 42/5.2/0847 ZYDUS HEALTHCARE SA 42/5.2/0848 ZYDUS HEALTHCARE SA BIO METRONIDAZOLE IV BISOPROLOL ZYDUS 5 TABLETS BISOPROLOL ZYDUS 10 TABLETS 42/20.1.1/1002 PHARMACARE LIMITED ASPEN LEVOFLOXACIN 5 mg/ml 42/26/1065 ACCORD HEALTHCARE 42/26/1066 ACCORD HEALTHCARE 42/7.1.5/1070 PHARMA DYNAMICS ACCORD OXALIPLATIN 100 INTAS OXALIPLATIN 100 DYNAFIL 25 mg Each 100,0 ml solution contains: METRONIDAZOLE 500,0 mg 5,0 mg Each 1,0 ml contains: LEVOFLOXACIN HEMIHYDRATE 5,0 mg OXALIPLATIN 100,0 mg OXALIPLATIN 100,0 mg SILDENAFIL CITRATE SILDENAFIL 25,0 mg 12.68_Notification_of Sep12_v1 Oct 2012 Page 3 of 10
4 42/7.1.5/1071 PHARMA DYNAMICS 42/7.1.5/1072 PHARMA DYNAMICS DYNAFIL 50 mg DYNAFIL 100 mg Notification of of Medicines SILDENAFIL CITRATE SILDENAFIL 50,0 mg SILDENAFIL CITRATE SILDENAFIL 100,0 mg 42/21.2/1089 MSD JANUMET 50/500 SITAGLIPTIN PHOSPHATE SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 500,0 mg 42/21.2/1090 MSD JANUMET 50/850 SITAGLIPTIN PHOSPHATE SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 850,0 mg 42/21.2/1091 MSD JANUMET 50/1 000 SITAGLIPTIN PHOSPHATE SITAGLIPTIN 50,0 mg METFORMIN HYDROCHLORIDE 1 000,0 mg 42/20.1.1/1098 STRIDES SA (PTY ) STRIDES AZITHROMYCIN 500 mg 43/21.12/0010 MEDIVISION MEDIVISION ANASTROZOLE 1 43/7.1.3/0059 ZYDUS HEALTHCARE SA 43/7.1.3/0060 ZYDUS HEALTHCARE SA 43/7.1.3/0061 ZYDUS HEALTHCARE SA 43/20.1.1/0245 ORCHID SA 43/2.2/0248 AUROBINDO PHARMA BISOPROLOL HYDROCHLORO- THIAZIDE ZYDUS 2,5/6,25 TABLETS BISOPROLOL HYDROCHLORO- THIAZIDE ZYDUS 5/6,25 TABLETS BISOPROLOL HYDROCHLORO- THIAZIDE ZYDUS 10/6,25 TABLETS ORCHID CEFPODOXIME 40 mg/5 ml AURO ZOLPIDEM 10 mg AZITHROMYCIN MONOHYDRATE AZITHROMYCIN 500,0 mg ANASTROZOLE 1,0 mg 2,5 mg 5,0 mg Each 5,0 ml suspension contains: CEFPODOXIME PROXETIL CEFPODOXIME 40,0 mg ZOLPIDEM TARTRATE 12.68_Notification_of Sep12_v1 Oct 2012 Page 4 of 10
5 43/2.2/0258 AUROBINDO PHARMA 43/1.2/0273 BE-TABS 43/1.2/0274 RANBAXY (SA) (PTY) 43/1.2/0275 BE-TABS 43/1.2/0276 RANBAXY (SA) (PTY) 43/1.2/0312 PHARMA DYNAMICS 43/1.2/0313 PHARMA DYNAMICS 43/1.2/0314 PHARMA DYNAMICS 43/1.2/0315 PHARMA DYNAMICS AURO ZOLPIDEM 5 mg BESIT 10 EPRALIFE 10 BESIT 20 EPRALIFE 20 DYNA ESCITALOPRAM 5 mg DYNA ESCITALOPRAM 10 mg DYNA ESCITALOPRAM 15 mg DYNA ESCITALOPRAM 20 mg Notification of of Medicines ZOLPIDEM TARTRATE 5,0 mg ESCITALOPRAM ESCITALOPRAM ESCITALOPRAM 20,0 mg ESCITALOPRAM 20,0 mg ESCITALOPRAM 5,0 mg ESCITALOPRAM ESCITALOPRAM 15,0 mg ESCITALOPRAM 20,0 mg 43/20.1.8/0388 PHARMACARE LIMITED VAVIREX 500 VALACICLOVIR HYDROCHLORIDE equivalent to VALACICLOVIR 500,0 mg 43/11.4.3/0483 SANDOZ SA TOPRALOC 20 PANTOPRAZOLE SODIUM SESQUIHYDRATE PANTOPRAZOLE 20,0 mg 43/11.4.3/0484 SANDOZ SA TOPRALOC 40 PANTOPRAZOLE SODIUM SESQUIHYDRATE PANTOPRAZOLE 40,0 mg 43/11.4.3/0485 SANDOZ SA HEXAL PANTOPRAZOLE 20 43/11.4.3/0486 SANDOZ SA HEXAL PANTOPRAZOLE 40 PANTOPRAZOLE SODIUM SESQUIHYDRATE PANTOPRAZOLE 20,0 mg PANTOPRAZOLE SODIUM SESQUIHYDRATE PANTOPRAZOLE 40,0 mg 12.68_Notification_of Sep12_v1 Oct 2012 Page 5 of 10
6 43/7.1/0558 BIOTECH LABORATORIES (PTY) 43/7.1/0559 BIOTECH LABORATORIES (PTY) BIO NIFEDIPINE XL 30 BIO NIFEDIPINE XL 60 Notification of of Medicines NIFEDIPINE 30,0 mg NIFEDIPINE 60,0 mg 43/2.6.5/0593 PHARMAPLAN ZOQIT 25 QUETIAPINE FUMARATE QUETIAPINE 25,0 mg 43/2.6.5/0594 PHARMAPLAN ZOQIT 100 QUETIAPINE FUMARATE QUETIAPINE 100,0 mg 43/2.6.5/0595 PHARMAPLAN ZOQIT 200 QUETIAPINE FUMARATE QUETIAPINE 200,0 mg 43/2.6.5/0596 PHARMAPLAN ZOQIT 300 QUETIAPINE FUMARATE QUETIAPINE 300,0 mg 43/13.1/0673 BARRS PHARMACEUTICAL INDUSTRIES cc 43/13.1/0674 BARRS PHARMACEUTICAL INDUSTRIES cc 43/2.2/0819 DR REDDY S LABORATORIES (PTY) 43/5.7.1/0912 SCHERING-PLOUGH 43/20.1.1/1087 CIPLA MEDPRO (PTY) 43/20.1.1/1088 CIPLA LIFE SCIENCES STERISCRUB STERISOL DRL ZOLPIDEM 10 DESELEX D-12 MEDPRO VANCOMAX 500 CIPLA VANCOMYCIN Each 100,0 ml solution contains: CHLORHEXIDINE GLUCONATE 20 % SOLUTION 20,0 ml Each 100,0 ml solution contains: CHLORHEXIDINE GLUCONATE 20 % SOLUTION 2,50 ml ZOLPIDEM TARTRATE DESLORATADINE 2,5 mg PSEUDOEPHEDRINE SULPHATE 120,0 mg VANCOMYCIN HCl equivalent to VANCOMYCIN 500,0 mg VANCOMYCIN HCl equivalent to VANCOMYCIN 500,0 mg 43/2.5/1142 PHARMAPLAN TOPIROL 50 TOPIRAMATE 50,0 mg 43/26/1171 CIPLA MEDPRO (PTY) 43/26/1172 CIPLA MEDPRO (PTY) ONCOGEM 200 ONCOGEM GEMCITABINE HYDROCHLORIDE equivalent to GEMCITABINE 200,0 mg GEMCITABINE HYDROCHLORIDE equivalent to GEMCITABINE 1 000,0 mg 12.68_Notification_of Sep12_v1 Oct 2012 Page 6 of 10
7 Notification of of Medicines 44/2.9/0113 PHARMAPLAN DEPODUR 10 PENTAHYDRATE 44/21.12/0281 CIPLA MEDPRO (PTY) 44/21.12/0282 CIPLE LIFE SCIENCES MEDPRO LETROZOLE 2,5 CIPLA LETROZOLE 2,5 LETROZOLE 2,5 mg LETROZOLE 2,5 mg 44/3.1/0331 NYCOMED XEFO RAPID LORNOXICAM 8,0 mg 44/26/0380 ACCORD HEALTHCARE 44/26/0381 ACCORD HEALTHCARE 44/2.6.5/0447 AKACIA HEALTHCARE 44/2.6.5/0448 AKACIA HEALTHCARE 44/2.6.5/0449 AKACIA HEALTHCARE 44/2.6.5/0450 AKACIA HEALTHCARE 44/2.6.5/0451 AKACIA HEALTHCARE 44/2.6.5/0452 AKACIA HEALTHCARE 44/2.6.5/0453 AKACIA HEALTHCARE 44/2.6.5/0454 AKACIA HEALTHCARE 44/7.1.3/0477 RANBAXY (SA) (PTY) 44/7.1.3/0478 RANBAXY (SA) (PTY) 44/7.1.3/0479 RANBAXY (SA) (PTY) 44/7.1.3/0482 RANBAXY (SA) (PTY) 44/7.1.3/0483 RANBAXY (SA) (PTY) INTAS OXALIPLATIN 50 ACCORD OXALIPLATIN 50 ZYLENA 5 ZYLENA 10 ZYLENA 15 ZYLENA 20 ZYLENA ODT 5 ZYLENA ODT 10 ZYLENA ODT 15 ZYLENA ODT 20 DIOLO CO PLUS 160/25 DIOLO CO 80/12,5 DIOLO CO 160/12,5 VALSARTAN RAN CO 160/25 VALSARTAN RAN CO 80/12,5 OXALIPLATIN 50,0 mg OXALIPLATIN 50,0 mg OLANZAPINE 5,0 mg OLANZAPINE OLANZAPINE 15,0 mg OLANZAPINE 20,0 mg OLANZAPINE 5,0 mg OLANZAPINE OLANZAPINE 15,0 mg OLANZAPINE 20,0 mg VALSARTAN 160,0 mg 25,0 mg VALSARTAN 80,0 mg 12,5 mg VALSARTAN 160,0 mg 12,5 mg VALSARTAN 160,0 mg 25,0 mg VALSARTAN 80,0 mg 12,5 mg 12.68_Notification_of Sep12_v1 Oct 2012 Page 7 of 10
8 44/7.1.3/0484 RANBAXY (SA) (PTY) 44/7.1.3/0560 RANBAXY (SA) (PTY) 44/7.1.3/0561 RANBAXY (SA) (PTY) 44/7.1.3/0562 RANBAXY (SA) (PTY) 44/7.1.3/0563 RANBAXY (SA) (PTY) 44/7.1.3/0564 RANBAXY (SA) (PTY) 44/7.1.3/0565 RANBAXY (SA) (PTY) VALSARTAN RAN CO 160/12,5 ZIRINAK 2,5/6,25 ZIRINAK 5/6,25 ZIRINAK 10/6,25 RAN BISOPROLOL CO 2,5/6,25 RAN BISOPROLOL CO 5/6,25 RAN BISOPROLOL CO 10/6,25 44/11.4.3/0595 SANDOZ SA SANDOZ RABEPRAZOLE 10 44/11.4.3/0596 SANDOZ SA SANDOZ RABEPRAZOLE 20 Notification of of Medicines VALSARTAN 160,0 mg 12,5 mg 2,5 mg 5,0 mg 2,5 mg 5,0 mg RABEPRAZOLE SODIUM RABEPRAZOLE SODIUM 20,0 mg 44/11.4.3/0597 SANDOZ SA RABEMED 10 RABEPRAZOLE SODIUM 44/11.4.3/0598 SANDOZ SA RABEMED 20 RABEPRAZOLE SODIUM 20,0 mg 44/21.2/0794 ALKEM LABORATORIES 44/21.2/0795 ALKEM LABORATORIES 44/7.1.3/0906 BRIMPHARM SA (PTY) METFORM ALKEM 500 METFORM ALKEM 850 IRTANEL 75 METFORMIN HYDROCHLORIDE 500,0 mg METFORMIN HYDROCHLORIDE 850,0 mg IRBESARTAN 75,0 mg 12.68_Notification_of Sep12_v1 Oct 2012 Page 8 of 10
9 44/7.1.3/0907 BRIMPHARM SA (PTY) 44/7.1.3/0908 BRIMPHARM SA (PTY) 44/7.1.3/0909 BRIMPHARM SA (PTY) 44/7.1.3/0910 BRIMPHARM SA (PTY) 44/7.1.3/0911 BRIMPHARM SA (PTY) 44/20.2.2/0932 JANSSEN PHARMACEUTICA (PTY) 44/1.2/1005 ZYDUS HEALTHCARE SA 44/1.2/1006 ZYDUS HEALTHCARE SA 44/1.2/1007 ZYDUS HEALTHCARE SA 44/1.2/1008 ZYDUS HEALTHCARE SA 44/20.2.8/1026 MACLEODS SA 44/20.2.8/1027 MACLEODS SA 44/20.2.8/1028 MACLEODS SA IRTANEL 150 IRTANEL 300 IRBESARTAN BRIMPHARM 75 IRBESARTAN BRIMPHARM 150 IRBESARTAN BRIMPHARM 300 DAK-O-GEL MIRTAZAPINE ZYDUS 15 mg MIRTAZAPINE ZYDUS 30 mg MIRADEP 15 mg MIRADEP 30 mg ROSTAV 15 ROSTAV 20 ROSTAV 30 Notification of of Medicines IRBESARTAN 150,0 mg IRBESARTAN 300,0 mg IRBESARTAN 75,0 mg IRBESARTAN 150,0 mg IRBESARTAN 300,0 mg Each 1,0 g gel contains: MICONAZOLE 20,0 mg MIRTAZAPINE 15,0 mg MIRTAZAPINE 30,0 mg MIRTAZAPINE 15,0 mg MIRTAZAPINE 30,0 mg STAVUDINE 15,0 mg STAVUDINE 20,0 mg STAVUDINE 30,0 mg 44/20.2.8/1051 PHARMACARE LIMITED TENARENZ TENOFOVIR DISOPROXIL FUMARATE 300,0 mg LAMIVUDINE 300,0 mg EFAVIRENZ 600,0 mg 44/2.9/1087 PHARMAPLAN DEPODUR 15 PENTAHYDRATE 15,0 mg 44/2.9/1088 PHARMAPLAN DEPODUR 20 PENTAHYDRATE 20,0 mg 45/5.7.2/0067 TEVA 45/5.7.2/0068 TEVA 45/20.2.8/0108 CIPLA MEDPRO (PTY) GRANISETRON TEVA 1 GRANISETRON TEVA 3 CIPLA LAMIVUDINE & TENOFOVIR 300/300 Each 1,0 ml solution contains: GRANISETRON HYDROCHLORIDE equivalent to GRANISETRON 1,0 mg Each 3,0 ml solution contains: GRANISETRON HYDROCHLORIDE equivalent to GRANISETRON 3,0 mg TENOFOVIR DISOPROXIL FUMARATE 300,0 mg LAMIVUDINE 300,0 mg 12.68_Notification_of Sep12_v1 Oct 2012 Page 9 of 10
10 45/20.2.8/0109 CIPLA LIFE SCIENCES 45/26/0145 CIPLA MEDPRO (PTY) 45/26/0146 CIPLA LIFE SCIENCES 45/8.2/0162 INGELHEIM 45/32.2/0540 BAROQUE 45/10.2.2/0744 CAMOX 45/10.2.2/0745 CAMOX 45/20.2.8/0887 MACLEODS SA MEDPRO LAMIVUDINE & TENOFOVIR 300/300 PURIDA CIPLA FLUDARABINE PRADAXA 150 XIENCE XPEDITION BELAIR 4 mg BELAIR 5 mg MACLEODS STAVUDINE 30 mg 45/20.2.8/0926 MYLAN MYLAN EMTRICITABINE 200 mg Notification of of Medicines TENOFOVIR DISOPROXIL FUMARATE 300,0 mg LAMIVUDINE 300,0 mg FLUDARABINE 50,0 mg FLUDARABINE 50,0 mg DABIGATRAN ETEXILATE MESILATE DABIGATRAN ETEXILATE 150,0 mg Each stent contains: EVEROLIMUS 100,0 µg/cm 2 Each chewable tablet contains: MONTELUKAST SODIUM MONTELUKAST 4,0 mg Each chewable tablet contains: MONTELUKAST SODIUM MONTELUKAST 5,0 mg STAVUDINE 30,0 mg EMTRICITABINE 200,0 mg 46/20.2.8/0006 MYLAN KAVIMUN PAED ABACAVIR SULPHATE ABACAVIR 60,0 mg 46/20.2.8/0008 MYLAN ZIDOMAT 100 mg ZIDOVUDINE 100,0 mg 46/20.2.8/0009 MYLAN ZIDOMAT 300 mg ZIDOVUDINE 300,0 mg 46/34/0023 NOVARTIS SA GILENYA 0,5 mg FINGOLIMOD HYDROCHLORIDE 0,5 mg MS MANDISA HELA REGISTRAR OF MEDICINES 12.68_Notification_of Sep12_v1 Oct 2012 Page 10 of 10
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 08/3.1.2/14 INGELHEIM A39/34/0605
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 08/5.1/09 INGELHEIM 08/5.1/10
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 41/20.1.1/0039 SCP MYLAN
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 42/2.5/0453 ZYDUS HEALTHCARE
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 07/3.1.2.2/23 NOVARTIS SA
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 30/2.10/0392 TEVA TEVA BACLOFEN
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 06/17.1.6/07 AFRIVET LOGISTICS
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 47/26/0920 SANOFI-AVENTIS
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) A05/11.5/08 A38/20.1.1/0406
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 36/20.1.2/0204 BIOTECH 36/20.1.2/0205
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 36/7.5/0281 PHARMACARE LIMITED
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
MEDICINES CONTROL COUNCIL
Notification of of Medicines MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)
COMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH
1 Abacavir Sulphate Antiretroviral - * - 2 Abiraterone Acetate Oncology - - - 3 Albendazole Anti-infective - - - 4 Albuterol Sulphate Respiratory - - 5 Alendronate Sodium Trihydrate Metabolic Disorder
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$4.00 WINDHOEK - 14 August 2013 No. 5263
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$4.00 WINDHOEK - 14 August 2013 No. 5263 CONTENTS Page GOVERNMENT NOTICES No. 211 No. 212 Request for submission of name of pharmacist for nomination for
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
EUROPEAN MEDICINES AGENCY DECISION. of 2 October 2009
European Medicines Agency Doc. Ref. EMEA/610520/2009 P/191/2009 EUROPEAN MEDICINES AGENCY DECISION of 2 October 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for alanine,
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$4.00 WINDHOEK - 26 July 2011 No. 4761
GOVERNMENT GAZETTE OF THE REPUBLIC OF N$4.00 WINDHOEK - 26 July 2011 No. 4761 CONTENTS Page GOVERNMENT NOTICE No. 122 Registration of certain medicines: Medicines and Related Substances Control Act, 2003...
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$2.00 WINDHOEK - 3 June 2011 No. 4726
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$2.00 WINDHOEK - 3 June 2011 No. 4726 CONTENTS Page GOVERNMENT NOTICE No. 71 Medicines and Related Substances Control Act, 2003: Registration of certain medicines...
MEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL NOTIFICATION OF REGISTRATION OF MEDICINES BY THE REGISTRAR IN TERMS OF SECTION 17 OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 Application Number Holder of registration
STANDARD FORMULATED SUPPLEMENTARY SPORTS FOODS
STANDARD 2.9.4 FORMULATED SUPPLEMENTARY SPORTS FOODS Purpose This Standard defines and regulates the composition and labelling of foods specially formulated to assist sports people in achieving specific
Product Name Strength Dosage Form Therapeutic Area Dossier Status. Aceclofenac 100mg Film coated Tablets Analgesia-inflammation Approved
Product Name Strength Dosage Form Therapeutic Area Dossier Status Aceclofenac 100mg Film coated Tablets Analgesia-inflammation Approved Alendronate Sodium 10/70mg Tablets Osteoporosis Approved Anastrozole
LIST OF FORMULATION PRODUCTS. Ferrocid Transule Capsule. Blended Pellets of Carbonyl Iron, Folic Acid & Zinc. Nature Biochem
LIST OF FORMULATION PRODUCTS Haematinics Ferrocid Transule Capsule Dried Ferrous Sulphate B.P. 1 Folic Acid B.P. 0.5 mg Eleron-F Dried Ferrous Sulphate I.P. 1 5 mg Cyanocobalamin I.P. 15 mcg Zinc Sulphate
PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6
Abiraterone Tablet 250 mg Q4 2016 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Available Alendronic Acid Tablet 70 mg Available Amikacin Solution for injection 50 mg/ml; 125mg/ml;
PRODUCT LIST GENERAL - TABLETS
SR. NO. PRODUCT LIST GENERAL - TABLETS 1 Ciprofloxacin Tablets IP 500 mg 2 Ciprofloxacin And Tinidazole Tablets 3 Cefpodoxime Proxetil Tablets IP 4 Cefixime Dispersible Tablets 200 mg 5 Cefixime Dispersible
Package leaflet: Information for the user. Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion
Package leaflet: Information for the user Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion Read all of this leaflet carefully before you start using
DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %
June 2016 On 13th May, the DH announced that there would be reductions to Category M prices from June until September. http://psnc.org.uk/our-news/contractor-notice-category-m-price-reduction/ This has
A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS. Pan-Canadian Select Molecule Price Initiative for Generic Drugs
Pharmacy Benefact A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS Number 723 February 2018 Pan-Canadian Select Molecule Price Initiative for Generic Drugs Alberta Drug Benefit List prices
This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2001L0015 EN 11.04.2006 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COMMISSION DIRECTIVE 2001/15/EC of 15 February
Food for special medical purposes. phenylketonuria (PKU) Important notice: Suitable only for individuals with proven phenylketonuria.
PKU Nutri 1 Energy Food for special medical purposes. For the dietary management of proven phenylketonuria (PKU) in infants from birth to 12 months and as a supplementary feed up to 3 years. An amino acid
Age-related reference ranges
Authoriser: Peter Beresford Page 1 of 6 Age-related reference ranges Alkaline Phosphatase (ALP) IU/L Both less than 14 days 90 273 Both 14 days
ATYPICAL ANTIPSYCHOTICS
Step Therapy CareOregon 2018 Last Updated: 07/27/2018 ATYPICAL ANTIPSYCHOTICS Fanapt Fanapt Titration Pack Paliperidone Er Vraylar The following criteria applies to members who newly start on the drug:
DT Description Price Category Price change
Tariff T Watch October 2014 Readers are no doubt aware of this quarter's bad news for primary care prescribing allocations: NHS England has d the remuneration mechanism for community pharmacies gaining
2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY 3. COMPOSITION OF THE MEDICINAL PRODUCT ml of the solution for infusion contain:
Title Page Information June 1999 1 (5) Aminoven infant 10% 1. NAME OF THE MEDICINAL PRODUCT Aminoven infant 10% 2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY For sale in pharmacies only
PORTFOLIO Q June 2014 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/5
Abiraterone Tablet 250 mg Q4 2015 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Q4 2014 Alendronic Acid Tablet 70 mg Available Amisulpride Tablet 50 ; 100 ; 200 ; 400 mg Available
Product Information: Phenex -1
Product Information: Phenex -1 1 of 5 For nutrition support of infants and toddlers with phenylketonuria (PKU). Phenylalanine-free Use under medical supervision. Phenylalanine-free to allow greater intake
EUROPEAN MEDICINES AGENCY DECISION. of 7 September 2009
European Medicines Agency Doc. Ref. EMEA/551360/2009 P/175/2009 EUROPEAN MEDICINES AGENCY DECISION of 7 September 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for
Product Information: Propimex -1
Product Information: Propimex -1 1 of 5 Nutrition support of infants and toddlers with propionic or methylmalonic acidemia. Methionine- and valine-free; low in isoleucine and threonine. Use under medical
Product Information: Tyrex -1
Product Information: Tyrex -1 1 of 5 Nutrition support of infants and toddlers with tyrosinemia types I, II or III. Phenylalanine- and tyrosine-free. Use under medical supervision. Phenylalanine- and tyrosine-free
Innovative Products Available. OTC Products Available
Innovative Products Benfotiamine film-coated tablets 150 mg Cholecalciferol film-coated tablets 22400 I.U. Diltiazem rectal ointment 2% Agents for Treatment of Hemorrhoids and Fissures Blood and Blood
0010 Amino Acid Analysis - 40 Plasma
770.446.5483 770.441.2237 This report contains reference range adjustments from routine revalidation procedures. It also contains the following three upgrades: 1) The amino acids have been reorganized
Product Information: Ketonex -1
Product Information: 1 of 5 Nutrition support of infants and toddlers with maple syrup urine disease (MSUD). Isoleucine-, leucine- and valine-free. Use under medical supervision. Branched-chain amino acid-free
Marketing authorisations granted in September 2012
PL 00037/0648 03/09/2012 ABBOTT LABORATORIES LIMITED LEVELANZ 250 MG FILM-COATED TABLETS LEVETIRACETAM 250 MILLIGRAMMES POM PL 00037/0649 03/09/2012 ABBOTT LABORATORIES LIMITED LEVELANZ 500 MG FILM-COATED
Vamin 18 EF QUALITATIVE AND QUANTITATIVE COMPOSITION
Title Page Information Dec. 2000 1 (7) Number Vamin 18 EF 121-01 1. NAME OF THE MEDICINAL PRODUCT Vamin 18 g N/l electrolyte-free infusion fluid, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1000
Official Journal of the European Communities
L 52/19 COMMISSION DIRECTIVE 2001/15/EC of 15 February 2001 on substances that may be added for specific nutritional purposes in foods for particular nutritional uses (Text with EEA relevance) THE COMMISSION
Product Information: EleCare Jr
Product Information: EleCare Jr 1 of 5 A 30 Cal/fl oz, nutritionally complete amino acid-based medical food for children age 1 and older who cannot tolerate intact or hydrolyzed protein. EleCare Jr is
COMMISSION REGULATION (EC)
14.10.2009 Official Journal of the European Union L 269/9 COMMISSION REGULATION (EC) No 953/2009 of 13 October 2009 on substances that may be added for specific nutritional in foods for particular nutritional
0010 Amino Acids 40 Profile - Plasma
Accession #: Order #: G1234567 Date Collected: Date Received: 01/22/2013 Reference #: Patient: Date of Birth: 02/05/1962 Date of Report: Telephone: 7704464583 Ordering Physician: 1234 Main St. Anywhere,
Amino Acid Analyzer AAA400
Amino Acid Analyzer AAA400 Determination of amino acid of hydrolyzates (food and feed) Column: LG ANB OSTION 3.6x340 12μm Eluents: sodium-citrate buffers, 0.2 M NaOH Aspartic Acid, Threonine, Serine, Glutamic
Product Category: EleCare
EleCare Product Category: EleCare EleCare (for Infants) Updated 4/28/2016 Product Information: EleCare (for Infants) 1 of 4 A 20 Cal/fl oz, nutritionally complete amino acid-based formula for infants who
Product Information: EleCare (for Infants)
1 of 5 Product Information: 2 of 5 A 20 Cal/fl oz, nutritionally complete amino acid-based formula for infants who cannot tolerate intact or hydrolyzed protein. EleCare is indicated for the dietary management
Product List Finished Dosage Forms (FDF) B2B Business
Product List 2017 Finished Dosage Forms (FDF) B2B Business Anaesthetics Dermatology Lidocaine Lidocaine and Prilocaine Dexmedetomidine Hydrochloride Anti-Infectives Amoxicillin Trihydrate and Potassium
TABLETS & CAPSULES. 8 Artemether + Lumafentarine Tablet (24 Tablet ) and Candesartan Tablet 8mg,16mg and 32 mg
TABLETS & CAPSULES Sr. No. Name of the product Strength 1 6-Mercaptopurine Tablets 50mg 2 Acetazolamide Tablet 250 mg 3 Al2O3 + Mg(OH)2 chewable Tablet 200 mg/200 mg 4 Allopurinol Tablet 100 mg 5 Ambroxol
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$5.60 WINDHOEK - 31 July 2012 No. 5003
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$5.60 WINDHOEK - 31 July 2012 No. 5003 CONTENTS Page GOVERNMENT NOTICES No. 186 Cancellation of certain medicines: Medicines and Related Substances Control
Amino Acids. Amino Acids. Fundamentals. While their name implies that amino acids are compounds that contain an NH. 3 and CO NH 3
Fundamentals While their name implies that amino acids are compounds that contain an 2 group and a 2 group, these groups are actually present as 3 and 2 respectively. They are classified as α, β, γ, etc..
MSUD HCU Tyrosinaemia MMA/PA IVA (for PKU cooler see pages 11-13)
(for PKU see pages 11-13) + Description A food for special medical purposes. Cooler is a ready-to-drink protein substitute containing essential and non-essential amino acids (but excluding the offending
+91-8048718516 Proton Pharma Private Limited http://www.protonpharma.in/ We are one of the leading manufacturer and distributors of high quality Medicines. Owing to highest level of quality standards,
ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)
ACTIVE PHARMACEUTICAL INGREDIENTS (APIs) Product Paracetamol/ Acetaminophen Ph.Eur & Metformin HCl Hypoglycemic Ph.Eur & Ibuprofen Analgesic Ph.Eur & Guaifenesin Mucolytic Ph.Eur & Muscle relaxant PHARMACEUTICAL
Nova Scotia Pharmacare Programs Interchangeable Product Updates November 13, 2018 New Categories
PAGE 1 OF 7 Nova Scotia Pharmacare Programs Interchangeable Product Updates November 13, New Categories A Maximum Reimbursable Price (MRP) or Pharmacare Reimbursement Price (PRP) has been established for
T1-1 Table 1. Target compounds and individual food additives.
T1-1 Table 1. Target compounds and individual food additives. No. 1 Aspartame Sweetener Aspartame D 1 1 2 Xylitol Sweetener Xylitol D 2 2 3 Glycyrrhizine Sweetener Disodium glycyrrhizinate D 3 3 Licorice
MSUD HCU Tyrosinaemia MMA/PA GA gel (for PKU gel see pages 7-10)
MSUD HCU Tyrosinaemia MMA/PA GA el (for PKU el see paes 7-10) Description A food for special medical purposes. Unflavoured powdered protein substitutes containin essential and non-essential amino acids
CONTACT POLPHARMA GROUP POLPHARMA B2B
DOSSIER FDFLIST Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM 1. Esomeprazole sodium or injection 40 mg Nexium / AstraZeneca Antiulcerant 2. Omeprazole
SUMMARY OF PRODUCT CHARACTERISTICS. Synthamin 14, 8.5% Amino Acid Intravenous Infusion
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Synthamin 14, 8.5% Amino Acid Intravenous Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION L-Leucine Ph. Eur 0.620% w/v L-Isoleucine
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference.
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference. Product Number API Test product Dose/ mg Manufacturer Country of manufacture Country
LAB#23: Biochemical Evidence of Evolution Name: Period Date :
LAB#23: Biochemical Evidence of Name: Period Date : Laboratory Experience #23 Bridge Worth 80 Lab Minutes If two organisms have similar portions of DNA (genes), these organisms will probably make similar
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT PRIMENE 10% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each litre of the infusion solution contains: L-Isoleucine L-Leucine L-Valine
ssniff Complete feeds for rabbits and guinea pigs *
ssniff Complete feeds for rabbits and guinea pigs * Complete diets for all development and life stages Comparable to other animal species also for the breeding and rearing of guinea pigs and rabbits higher
NBPDP Formulary Update
Bulletin # 830 April 4, 2012 NBPDP Formulary Update Please find attached lists of interchangeable product additions to the New Brunswick Prescription Drug Program Formulary and non-listed products subject
TENDER RESULTS. Notification of Product Changes (NOPC) forms and Pharmacodes
30 June 2014 TENDER RESULTS PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October
DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY
tlo_seledyn.pdf 1 22.08.2017 14:38:01 C M Y CM MY CY CMY K DOSSIER LIST tlo_seledyn.pdf 1 22.08.2017 14:38:01 PRODUCT NAME PHARMACEUTICAL FORM STRENGTH REFERENCE THERAPEUTIC CLASS ALIMENTARY TRACT & METABOLISM
1. Describe the relationship of dietary protein and the health of major body systems.
Food Explorations Lab I: The Building Blocks STUDENT LAB INVESTIGATIONS Name: Lab Overview In this investigation, you will be constructing animal and plant proteins using beads to represent the amino acids.
Visual evaluation of early (~ 4-cell) mammalian embryos. How well does it predict subsequent viability? Marie-Noël Bruné Rossel APPENDICES
Visual evaluation of early (~ 4-cell) mammalian embryos. How well does it predict subsequent viability? Marie-Noël Bruné Rossel APPENDICES 1) Glossary (alphabetical) (From the Aberdeen Fertility Centre
Table A1: Fifty Most Often Repeated Oral Drug Product Shortages (35 ingredients), Canada,
1 Appendix Commentary 515 Appendix: Assessing Canada s Drug Shortage Problem Table A1: Fifty Most Often Repeated Oral Drug Product Shortages (35 ingredients), Canada, 2013 16 Drug Name Dosage Therapeutic
Lecture 3: 8/24. CHAPTER 3 Amino Acids
Lecture 3: 8/24 CHAPTER 3 Amino Acids 1 Chapter 3 Outline 2 Amino Acid Are Biomolecules and their Atoms Can Be Visualized by Two Different Ways 1) Fischer projections: Two dimensional representation of
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013 Sl. No. F.No. Name of the Company/ Formulation Date of receipt of application
While there is around a 3% increase shown in costs for Category M lines, I think this is due to the inclusion of more lines in Category M.
April 2018 The usual quarterly of Category M prices Another set of similar comments as I made in January: significant increases in many lines which have been subject to price concessions but even more
Full Report (All Nutrients) 01174, Milk, reduced fat, fluid, 2% milkfat, without added vitamin A and vitamin D
National base for Standard Reference Release 28 slightly revised May, 206 Full Report (All s) 074, Milk, reduced fat, fluid, 2% milkfat, without added vitamin A and vitamin D Report Date: February 23,
(a) (i) Describe how the production and action of interferon differs from the production and action of lysozyme. (3)
1 Histamine and the proteins interferon and lysozyme are involved in the non-specific responses to infection. (a) (i) escribe how the production and action of interferon differs from the production and
ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS
SR. NO 1 ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS Paracetamol 500 mg, Phenylephrine HCL 5 mg With Chlorpheniramine Maleate 2 mg & Caffeine 30 mg Tablets 2 Salbutamol Tablets BP 2 mg 3 Salbutamol Tablets
MABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS
ICON Formulary - November 2016 Class Medicine Name Nappi Strength Form Size Route Manufacturer Abiraterone Acetate ZYTIGA 250 720690001 250 mg 120 ORAL JANSSEN PHARMACEUTICALS Aldesleukin CHIRON IL-2 18
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs ZOLOFT (sertraline hydrochloride) tablets, for oral use This list does not imply that the products on this chart are interchangeable or have the
DYMATIZE ELITE 100% WHEY The perfect anytime protein
DYMATIZE ELITE 100% WHEY The perfect anytime protein Product description The perfect anytime protein! Are you looking for an anytime protein with great value? Whether you re supporting muscle growth after
Table 1: Price increases for Brand Name Drugs with Generic Equivalents
Table 1: Price increases for Brand Name Drugs with Generic Equivalents Brand Name Medication and Dose Total % Change Since 10/2012 ACTOS 15 MG TABLET 6.36 11.03 73.39% ACTOS 30 MG TABLET 9.7 16.80 73.23%
CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 702 M %
December 16 No Category M changes so the reductions imposed in May which were only supposed to last until September continue As in November, most changes are Category A lines with a few Category C. Significant
6 Each Film coated Tablet Contains :- Ofloxacin 200 mg 10 x 10 Alu
PRODUCT MANUFACTURING LIST Tablet SECTIONS :- S.No. Composition Claim Pack Size Packing Type Remarks 1 Each Film coated Tablet Contains :- Ofloxacin 200 mg 10 x 10 Alu 2 Each Film coated Tablet Contains
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA. N$4.00 WINDHOEK - 26 February 2013 No. 5142
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$4.00 WINDHOEK - 26 February 2013 No. 5142 CONTENTS Page GOVERNMENT NOTICES No. 30 Notification of registration of certain medicines: Medicines and Related
Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column
Application Note Pharmaceutical and Food Testing Analysis of Amino Acids Derived Online Using an Agilent AdvanceBio AAA Column Author Lu Yufei Agilent Technologies, Inc. Abstract A liquid chromatographic
Proteins consist in whole or large part of amino acids. Simple proteins consist only of amino acids.
Today we begin our discussion of the structure and properties of proteins. Proteins consist in whole or large part of amino acids. Simple proteins consist only of amino acids. Conjugated proteins contain
Aurobindo Pharma Ltd. et al.; Withdrawal of Approval of Eighty-Six Abbreviated New Drug
This document is scheduled to be published in the Federal Register on 06/19/2014 and available online at http://federalregister.gov/a/2014-14288, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Metabolism of Amino Acids in Aquatic Animals II
Mem. Fac. Fish., Kagoshima Univ. Vol. 26 pp. 45-48 (1977) Metabolism of Amino Acids in Aquatic Animals II The effect of an amino acid supplemented casein diet on the growth rate of carp Yoshito Tanaka,
INFANT NUTRITION AGRANA
INFANT NUTRITION AGRANA STARCH INFANT FORMULA Quality and expertise The key values of AGRANA s Infant Formula range Our high quality Austrian Infant Formula has been formulated against our expert knowledge
[NOTE The relative retention times for calcitonin salmon and calcitonin salmon related compound A Change to read:
. Mode: Revision Bulletin Official April 1, 2012 Calcitonin Salmon 1 LC Calcitonin Salmon Detector: UV 220 nm Column: 4.6-mm 25-cm; packing L1 Column temperature: 65 Flow rate: 1 ml/min Injection volume:
+91-8071678267 Biovaxia Pharma http://www.biovaxia.com/ We are engaged in the specified business of manufacturer, supplier, trader & exporter of Pharmaceutical Tablet and Injections. Offered medicinal
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DUPHALYTE Solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Composition per ml VITAMINS
Medicines availability short-term supply issues Last updated 01/05/18
Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is
TRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because